640
Views
13
CrossRef citations to date
0
Altmetric
Commentary

A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?

, &
Pages 737-738 | Published online: 06 Apr 2010

Pneumocystis is one of the more frequent infections seen in immune-compromised patients, and usually manifests as a disseminated and life-threatening pneumonia (PCP). Because of this, consideration of prophylaxis is important for these patients. Understanding more about the infectious agent, Pneumocystis, and the disease it causes, may add much in the successful treatment and more importantly in prevention of the infection in these patients [Citation1].

Recently, a number of studies on the biology and immunology of the organism have been reported, and new concepts in relation to Pneumocystis are emerging [Citation2,Citation3]. First, it is now recognized that each mammalian host is infected by a specific organism, which does not infect another host. Furthermore, it is worth recalling that the infective organism, Pneumocystis carinii, which causes the infection in humans, has been renamed Pneumocystis jirovecii, after Otto Jirovec, who is credited with first describing the microbe in humans [Citation4]. Second, new evidence suggests that PCP is not really a result of reactivation of a dormant infection occurring during immune suppression, as always believed, but rather a re-infection from an as yet unidentified human or environmental source [Citation3]. The third, and most intriguing recent observation, relates to the fact that immunity to Pneumocystis is no longer regarded just as a single arm response, restricted only to CD4+ T-lymphocytes, but in fact consists of a dynamic interplay between every arm of the immune system, involving the innate immunity within the pulmonary environment, where alveolar macrophages play a central role, and the adaptive immune response, in which activated alveolar macrophages stimulate both cellular and antibody responses [Citation3]. Consequently, a low CD4 count (<200 cells/mm3) is probably not the only criterion that should be used in deciding whether a particular patient is at risk for PCP and requires prophylaxis therapy.

It is indeed possible that Pneumocystis infection may once again be emerging out of the shadows, as in the 1980s when human immunodeficiency virus (HIV) infection became widespread, and PCP infections became common.

In this issue of Leukemia and Lymphoma, Kamel et al. report that among 47 patients with aggressive B-cell lymphoma treated with R-CHOP-14 (biweekly rituximab, cyclophosphamide, adriamycin, vincristine, prednisone), five (11% of patients) developed microbiologically proven PCP during therapy [Citation5]. This phenomenon is notable, because in patients receiving other CHOP schedules (CHOP-21 or R-CHOP-21, given 3-weekly); the risk of PCP is negligible [Citation6,Citation7]. Others have also reported opportunistic infections using dose-intense R-CHOP-14 therapy [Citation6] and variants, including R-CHOEP-14 (R-CHOP combination with etoposide) [Citation7]. In most of these patients the number of CD4+ T-lymphocytes was above 200 cells/mm3, and immunoglobulin levels were within the normal range [Citation5–7].

What is the most likely cause for the increased risk of PCP in patients receiving the R-CHOP-14 based regimens? As Kamel et al. suggest, it seems most likely that the reason for the increased risk for PCP is the increased intensity of corticosteroid exposure, as well as the cumulative dose of the drug [Citation5]. On the other hand, other possibilities should be kept in mind. Might the B-cell depletion caused by rituximab play a role? The German non-Hodgkin lymphoma (NHL) study group compared CHOP-21 to CHOP-14 (and CHOEP-21 to CHOEP-14), without rituximab, and did not record an increased rate of PCP in the intensified protocols [Citation8,Citation9]. This observation, in retrospect, suggests that in NHL, rituximab may well be implicated or contribute to the development of interstitial pneumonitis and other respiratory tract infections [Citation10] when given together with combination chemotherapy, or even as monotherapy [Citation10]. This risk appears to be heightened when an intensive schedule of rituximab is employed, so prophylactic antibiotics have been suggested in that setting [Citation11]. However, case reports have even described the association of the use of rituximab as a single agent and the development of PCP [Citation12–14]. Taking this into consideration, it is hard to exclude the possibility that rituximab may contribute to the risk of PCP development, when used in the context of a steroid-dense R-CHOP-14 schedule. Notably, recent reports suggest that standard R-CHOP-21 is just as effective as R-CHOP-14, and perhaps less toxic [Citation15].

In conclusion, we indeed appear to be dealing with a phenomenon that looks like a reappearance of a relatively small number of ‘reactivated’ cases of an already controlled infectious disease caused by Pneumocystis. Clinicians should take note, and consider prophylaxis in appropriate settings. In the future, the therapeutic options may also include a vaccine against Pneumocystis [Citation3]. This development would bring with it the hope for better control of PCP, or even for eliminating Pneumocystis infection completely.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  • Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3): CD005590.
  • Calderon EJ. Pneumocystis infection: seeing beyond the tip of the iceberg. Clin Infect Dis 2010;50:354–356.
  • Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol 2010;5:43–65.
  • Stringer JR, Beard CB, Miller RF. A new name (Pnemocystis jiroveci) for pneumocystis in humans. Emerg Infect Dis 2002;8:891–896.
  • Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:797–801.
  • Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008;80:275–276.
  • Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139–140.
  • Wunderlich A, Kloess M, Reiser M, et al Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881–893.
  • Pfreundschuh M, Trümper L, Kloess M, et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
  • Katsuya H, Suzumiya J, Sasaki H, et al Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818–1823.
  • Pfreundschuh M, Zeynalova S, Poeschel V, et al Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNH). Blood 2007;110(Suppl. 1): (Abstract 789).
  • Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009;14:696–699.
  • Gentner J, Morra M, Knutsen AP. Development of common variable immunodeficiency in an 8-year-old boy treated with rituximab for idiopathic thrombocytopenia. Pediatr Asthma Allergy Immunol 2008;21:99–104.
  • Teichmann LL, Woenckhaus M, Vogel C, Salzberger B. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology 2008;47:1256–1257.
  • Delarue R, Haioun C, Ribrag V, et al R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study. Blood 2009;114(Suppl. 1): (Abstract 406).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.